From MELVYL@UCCMVSA.UCOP.EDU Sat Nov 9 02:16:47 1996
Date: Fri, 08 Nov 96 21:46:02 PST
From: Melvyl System
To: medline@pinch.com
Subject: (id: BEQ21903) MELVYL system mail result
Search request: F KW PSORIASIS AND TREATMENT AND OIL
Search result: 10 citations in the Medline database
Display: ABS
1. Katayama I; Minatohara K; Yokozeki H; Nishioka K.
Topical vitamin D3 downregulates IgE-mediated murine biphasic cutaneous
reactions.
International Archives of Allergy and Immunology, 1996 Sep, 111(1):71-6.
(UI: 96354672)
AT: UCSF Library W1 IN 704 Journals 1, 1950/51-. Currently received.
(PE title: International archives of allergy and immunology.)
Abstract: Hapten-specific and mast-cell-dependent biphasic (immediate and
delayed-onset) cutaneous reactions were induced in a murine model by
intravenous injection of anti-DNP IgE antibodies followed by a skin test.
Four daily applications of topical 1 alpha,24(OH)2D3 ointment significantly
inhibited both the immediate and the delayed-onset cutaneous reactions in a
dose-dependent fashion, as well as the croton-oil-induced cutaneous
reaction and DNFB contact sensitivity reaction. 1 alpha,24(OH)2D3 itself
did not show any sensitizing or irritant potential. The inhibitory effect
of 1 alpha,24(OH)2D3 on these reactions was limited to the application site
and no systemic effect was observed. Another vitamin D3 analog 1
alpha,25(OH)2D3, also showed an inhibitory effect on IgE-mediated cutaneous
reactions. These results suggest that topically applied 1 alpha,24(OH)2D3
might modulate IgE-mediated cutaneous reactions and could thus be useful in
the treatment of certain human cutaneous disorders other than psoriasis and
related keratinizing disorders.
2. Schopf E; Mueller JM; Ostermann T.
[Value of adjuvant basic therapy in chronic recurrent skin diseases.
Neurodermatitis atopica/psoriasis vulgaris].
Hautarzt, 1995 Jul, 46(7):451-4.
Language: German.
Pub type: Journal Article; Review; Review, Tutorial.
(UI: 95403152)
AT: UCSF Library W1 HA 899 2nd Floor 39-42, 1988-91. Subscription
cancelled.
NRLF W1 HA 899 11-38, 1960-87.; Type EXP NRLF
for loan details. Subscription cancelled.
(PE title: Hautarzt, Zeitschrift fur Dermatologie, Venerologie und
verwandte Gebiete.)
Abstract: Atopic dermatitis and psoriasis vulgaris belong to the most common
diseases in dermatology. Since these chronical diseases progress over years
and decades, they may lead to restrictions in private and professional life
as well as to psychological stress of concerned patients. Therefore, a
lasting, stabilising, stage-adjusted topical treatment is necessary. Main
component of this treatment in a complete therapeutical concept consists in
an adjuvant basic therapy with oil baths and with emollients containing
urea or no drug additives at all. Thus the vehicle itself is
therapeutically effective. Altered structure and function of the skin
measured by increased transepidermal water loss, dysfunction of skin lipid
barrier, augmented skin permeability and skin roughness can be improved.
Due to this treatment clinical symptoms can be diminished and relapses can
be avoided. Corticosteroids and other specific medications can be reduced
by using basic therapeutics with little side effects. This means economical
benefit as well. So far adjuvant basic treatment is an essential part in
the therapy of chronic inflammatory skin diseases.
3. Lebwohl M; Martinez J; Weber P; DeLuca R.
Effects of topical preparations on the erythemogenicity of UVB:
implications for psoriasis phototherapy.
Journal of the American Academy of Dermatology, 1995 Mar, 32(3):469-71.
(UI: 95173224)
AT: UCSF Library W1 JO 2J Journals 1, 1979-. Currently received.
UCSF Mt. Zion Journals v. 1, 1979-
UCSF SFGH No call number Journals
2, 1980-. Currently received.
(PE title: Journal of the American Academy of Dermatology.)
Abstract: BACKGROUND: Topical preparations are sometimes applied before
phototherapy without consideration of their potential to block UVB.
OBJECTIVE: Our purpose was to examine the ability of topical preparations
to block UVB. METHODS: Volunteers pretreated with mineral oil, a clear
liquid emollient, 5% crude coal tar, 6% salicylic acid ointment, emollient
creams, and petrolatum underwent minimal erythema dose testing.
Transmission of UVB through a clear film coated with the preparations was
measured. RESULTS: Tars and salicylic acid blocked UVB. Thick application
of petrolatum and emollient creams can reduce transmission of UVB. Mineral
oil and a clear liquid emollient did not significantly affect transmission
or erythemogenicity of UVB. CONCLUSION: Clear liquid emollient and mineral
oil can be used before phototherapy. If not removed before phototherapy,
preparations containing tar or salicylic acid, or thickly applied
petrolatum or emollients, can block UVB and presumably reduce its efficacy
in the treatment of psoriasis.
4. Veale DJ; Torley HI; Richards IM; O'Dowd A; Fitzsimons C; Belch JJ; Sturrock
RD.
A double-blind placebo controlled trial of Efamol Marine on skin and joint
symptoms of psoriatic arthritis.
British Journal of Rheumatology, 1994 Oct, 33(10):954-8.
Pub type: Clinical Trial; Journal Article; Randomized Controlled Trial.
(UI: 95005998)
AT: UCSF Library W1 BR 625F Journals 22, 1983-. Currently received.
(PE title: British journal of rheumatology.)
AT: UCSF Library W1 BR 625F Journals 1983-. Currently received.
(PE title: British Journal of Rheumatology. Supplement.)
Abstract: Fish oil may be beneficial in the treatment of psoriasis and in RA.
We examined the potential benefit of Efamol Marine, a combination of
evening primrose oil and fish oil in the treatment of 38 patients with PsA.
Patients with PsA were entered in a double-blind placebo controlled study
and received either 12 Efamol Marine capsules or 12 placebo capsules daily
for 9 months. All patients received placebo capsules for a further 3
months. At month 3 of the study patients were asked to reduce their intake
of NSAIDs and maintain that decrease provided there was no worsening of
their joint symptoms. Clinical assessments of skin and joint disease
severity and activity were performed at 0, 1, 3, 6, 9 and 12 months. All
measures of skin disease activity including severity, percentage body
affected and itch were unchanged by Efamol Marine. The NSAID requirement
remained the same between both treatment groups. In addition, there was no
change demonstrated in the activity of arthritis as measured by duration of
morning stiffness. Ritchie articular index, number of active joints, ESR
and CRP. However, a rise in serum TXB2 was observed in the active group
during the placebo phase; in addition a fall in leukotriene B4 production
occurred during the active phase period followed by a marked rise during
the placebo phase suggesting some laboratory documented anti-inflammatory
effect. In conclusion, this study suggests that Efamol Marine may alter
prostaglandin metabolism in patients with PsA, although it did not produce
a clinical improvement and did not allow reduction in NSAID requirement. A
larger dose of essential fatty acid may be needed to produce a clinical
benefit.
5. Soyland E; Funk J; Rajka G; Sandberg M; Thune P; Rustad L; Helland S;
Middelfart K; Odu S; Falk ES; et al.
Dietary supplementation with very long-chain n-3 fatty acids in patients
with atopic dermatitis. A double-blind, multicentre study.
British Journal of Dermatology, 1994 Jun, 130(6):757-64.
Pub type: Clinical Trial; Journal Article; Multicenter Study; Randomized
Controlled Trial.
(UI: 94281044)
AT: UCSF Library W1 BR 526 Journals 63, 1951-. Currently received.
UCSF SFGH No call number Journals
92, 1975-. Currently received.
(PE title: British journal of dermatology (1951).)
Abstract: The purpose of this study was to investigate whether fish oil and/or
corn oil had a beneficial effect on the clinical state of atopic
dermatitis, and to evaluate the dietary intake of nutrients in this group
of patients. In a double-blind, multicentre study lasting 4 months, during
wintertime, 145 patients with moderate to severe atopic dermatitis were
randomly assigned to receive either 6 g/day of concentrated n-3 fatty
acids, or an isoenergetic amount of corn oil. As local treatment, only an
emollient cream or hydrocortisone cream was allowed. The fatty acid pattern
in serum phospholipids, and the dietary intake of nutrients were monitored
in a subgroup of patients, and the results were compared with a group of
patients with psoriasis. The overall clinical score, as evaluated by the
physicians, improved during the trial by 30% in the fish oil (P < 0.001)
and 24% in the corn oil group (P < 0.001). This was also consistent with
the results from a selected skin area, and it was further confirmed by the
total subjective clinical score reported by the patients. There were no
significant differences in the clinical scores between the two groups at
baseline, and at the end of the study. In the fish oil group, the amount of
n-3 fatty acids in serum phospholipids was significantly increased at the
end of the trial, compared with pretreatment values (P < 0.001), whereas
the level of n-6 fatty acids was decreased (P < 0.001).(ABSTRACT TRUNCATED
AT 250 WORDS)
6. Oliwiecki S; Burton JL.
Evening primrose oil and marine oil in the treatment of psoriasis.
Clinical and Experimental Dermatology, 1994 Mar, 19(2):127-9.
Pub type: Clinical Trial; Journal Article; Randomized Controlled Trial.
(UI: 94326401)
AT: UCSF Library W1 CL 656 Journals 1, 1976-. Currently received.
(PE title: Clinical and experimental dermatology.)
Abstract: The effect of dietary supplementation with a combination of n-3
(marine oil) and n-6 (evening primrose oil) essential fatty acids in the
treatment of chronic stable plaque psoriasis was observed. Thirty-seven
patients in a double-blind parallel trial were studied. There was no
significant improvement in clinical severity of psoriasis or change in
transepidermal water loss.
7. Frati C; Bevilacqua L; Apostolico V.
Association of etretinate and fish oil in psoriasis therapy. Inhibition of
hypertriglyceridemia resulting from retinoid therapy after fish oil
supplementation.
Acta Dermato-Venereologica. Supplementum, 1994, 186:151-3.
(UI: 94353868)
AT: UCSF Library W1 AC 7921 SUPPL. Journals
1, 1929-. Currently received.
UCSF Library No call number Books For holdings, consult UCSF local
catalog.
(PE title: Acta Dermato-Venereologica. Supplementa.)
Abstract: We studied the main papers concerning treatment with fish oil (EPA
and DHA) of patients with psoriasis vulgaris, psoriatic arthritis and
pustular psoriasis. In our investigation, 25 patients with psoriasis
vulgaris evidenced a statistically significant increase in triglyceride
serum levels, compared with controls. 10 of these patients underwent
therapy with etretinate 0.75-1.0 mg/kg daily for 2 months followed by 2-3
months of etretinate 0.35-0.50 mg/kg daily associated with fish oil 1.5 g
(EPA and DHA) daily. According with several authors, fish oil is able not
only to produce good clinical results, but also to minimize the side
effects of retinoid therapy, especially hypertriglyceridemia.
8. Duncan JI; Wakeel RA; Winfield AJ; Ormerod AD; Thomson AW.
Immunomodulation of psoriasis with a topical cyclosporin A formulation.
Acta Dermato-Venereologica, 1993 Apr, 73(2):84-7.
Pub type: Clinical Trial; Controlled Clinical Trial; Journal Article.
(UI: 93370080)
AT: UCSF Library W1 AC 7921 Journals 1, 1920-. Currently received.
(PE title: Acta dermato-venereologica.)
Abstract: Topical cyclosporin A (CyA; Sandimmun) in a formulation incorporating
the penetration enhancers (PE) propylene glycol (18%) and azone (2%) was
tested for efficacy in a double-blind, vehicle-controlled trial in 5
chronic plaque psoriatic patients. On each patient, two similar plaques
were treated daily, under occlusion, for 4 weeks with either 8% (w/v) CyA,
containing PE, or with vehicle comprising olive oil with PE. All sites
improved significantly, but there was no significant difference between
those receiving active and control preparations. Cryostat sections of
biopsies performed after 4 weeks' treatment showed significant reductions
in CyA compared with vehicle-treated sites in the number of cells, positive
for CD3 and CD25 in the epidermis and CD25 and HLA-DR in the dermis. These
results suggest that amounts of CyA adequate to affect the lymphocytic
infiltrate penetrated the epidermis but that only partial suppression
occurred in the dermis, as indicated by the reduction in lymphocyte
activation status.
9. Watsky KL; Freije L; Leneveu MC; Wenck HA; Leffell DJ.
Water-in-oil emollients as steroid-sparing adjunctive therapy in the
treatment of psoriasis.
Cutis, 1992 Nov, 50(5):383-6.
(UI: 93105679)
AT: UCSF Library W1 CU 97 Journals 1, 1965-. Currently received.
(PE title: Cutis.)
Abstract: An open label study of ninety-six patients with chronic plaque-type
psoriasis demonstrated the efficacy of the addition of water-in-oil
emollients to a topical corticosteroid regimen. Twice daily application of
betamethasone dipropionate cream and once daily application of both
betamethasone dipropionate cream and either a water-in-oil based
moisturizing cream or lotion were equivalent in efficacy (p = 0.05). Once
daily application of both betamethasone dipropionate cream and either a
water-in-oil based cream or lotion was significantly better than once daily
application of betamethasone dipropionate cream alone (p = 0.05).
Water-in-oil emollients are useful in the therapy of chronic, plaque-type
psoriasis and provide a steroid-sparing effect.
10. Escobar SO; Achenbach R; Iannantuono R; Torem V.
Topical fish oil in psoriasis--a controlled and blind study.
Clinical and Experimental Dermatology, 1992 May, 17(3):159-62.
Pub type: Clinical Trial; Journal Article; Randomized Controlled Trial.
(UI: 93082895)
AT: UCSF Library W1 CL 656 Journals 1, 1976-. Currently received.
(PE title: Clinical and experimental dermatology.)
Abstract: Omega-3 polyunsaturated fatty acids compete with arachidonic acid as
substrates for lipoperoxidases, which transform them into leukotrienes with
low biological activity. As this process, in skin, may benefit psoriatic
patients, a randomized controlled single blind-study was carried out on a
sample of 25 patients. In the study fish oil (FO) was compared with liquid
paraffin (LP); both were topically applied and administered daily for 6 h
under an occlusive dressing over a 4-week period. Evaluations were
performed weekly assessing erythema, scaling, plaque thickness (induration)
and itching. The results showed statistically significant improvement in
erythema and scaling for both treatments compared to basal values;
significant differences between treatments were achieved in scaling but not
in erythema. Compared to baseline, FO significantly improved plaque
thickness while LP did not. After 4 weeks, FO proved to be significantly
better than LP. All patients accepted the treatment despite its unpleasant
smell. Irritation and a burning sensation were reported in the FO treated
plaque of one patient. This adverse effect reverted after completing the
treatment. These findings demonstrate that topical FO shows a better
performance than LP under an occlusive dressing.